Login to Your Account

Insmed Shares Tumble on Failed Phase II Iplex Trial

By Donna Young

Friday, June 26, 2009
Insmed Inc.'s stock lost more than half of its value Thursday after the Richmond, Va.-based firm said Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor 1 (IGF-1) and its binding protein IGFBP-3, failed to improve endurance, muscle function or strength or quality of life in patients with myotonic muscular dystrophy (MMD), a potentially life-threatening genetic disorder. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription